Annals of Oncology
Official Journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology

**editor-in-chief:**
J.-C. Soria, Villejuif, France

**associate editors**

- **Urogenital tumors**
  - G. Attard, Sutton, UK
  - M. De Santis, Vienna, Austria
- **Gastrointestinal tumors**
  - J. Tabernero, Barcelona, Spain
  - A. Cervantes, Valencia, Spain
- **Breast tumors**
  - F. André, Villejuif, France
  - C. Sotiriou, Brussels, Belgium
- **Thoracic tumors**
  - T. Mitsudomi, Osaka, Japan
  - J. F. Vansteenkiste, Leuven, Belgium
- **Head and neck tumors**
  - A. T. C. Chan, Shatin, Hong Kong

**editors emeriti**

- F. Cavalli, Bellinzona, Switzerland
- D. J. Kerr, Oxford, UK
- J. B. Vermorken, Edegem, Belgium
- C. Bonadonna, Turin, Italy
- L. G. H. N. Verweij, Amsterdam, Netherlands
- R. Pinto, Lissabon, Portugal
- J. W. G. Johnson, Oxford, UK
- D. S. Grunberg, New York, USA

**Thoracic tumors**

- S. Pignata, Naples, Italy
- C. Robert, Villejuif, France
- K. Tsukasaki, Kashihara, Japan
- P. L. Zanoni, Bologna, Italy
- K. Jordan, Halle, Germany
- P. Boffetta, New York, New York, USA
- O. Mir, Villejuif, France

**Gynecological tumors**

- S. Gatta, Turin, Italy
- D. Morganroth, New York, USA
- C. Robert, Villejuif, France
- U. Dürselen, Wuppertal, Germany
- H. Iwata, Aichi, Japan
- F. Janku, Houston, Texas, USA
- N. Katsumata, Kawasaki, Japan
- N. Kiyota, Kobe, Japan
- P. N. Jr Lara, Rio de Janeiro, Brazil
- B. Rini, Birmingham, USA
- M. Reck, Munich, Germany
- S. S. Ramalingam, Atlanta, USA
- H.-I. Schmolz, Halle, Germany
- I. Sekine, Chiba, Japan
- X. Paolotti, Paris, France
- P. Pfeiffer, Odense, Denmark
- S. V. Porceddu, Brisbane, Australia
- M. R. Posner, New York, USA
- S. Postel-Vinay, Villejuif, France
- A. Poyri, New Haven, Connecticut, USA
- D. Quinn, Los Angeles, California, USA
- S. Ramalingam, Atlanta, Georgia, USA
- M. Reck, Grosshansdorf, Germany
- B. Rini, Cleveland, Ohio, USA
- R. Rosell, Badalona, Spain
- A. D. Roth, Geneva, Switzerland
- R. Salazar, Barcelona, Spain
- M. Scartozi, Arconà, Italy
- N. Schmitz, Hamburg, Germany
- H.-I. Schmolz, Halle, Germany
- I. Sekine, Chiba, Japan
- Q. Shi, Rochester, Minnesota, USA
- A. F. Sobrero, Genoa, Italy
- G. Sonpavde, Birmingham, Alabama, USA
- S. Takahashi, Tokyo, Japan
- M. Toi, Kyoto, Japan
- E. Vilar, Houston, Texas, USA
- Y.-L. Wu, Guangzhou, China
- J. C.-H. Yang, Taipei, Taiwan
- S. Yano, Kanazawa, Japan

**Melanoma**

- A. Goldhirsch, Milan, Italy
- R. Govindan, St. Louis, Missouri, USA
- P. Grimison, Sydney, Australia
- D. G. Haller, Philadelphia, Pennsylvania, USA
- R. A. Huddart, Sutton, UK
- I. Hyodo, Tsukuba, Japan
- H. Iwata, Aichi, Japan
- F. Janku, Houston, Texas, USA
- N. Katsumata, Kawasaki, Japan
- N. Kiyota, Kobe, Japan
- P. N. Jr Lara, Rio de Janeiro, Brazil
- B. Rini, Birmingham, USA
- M. Reck, Munich, Germany
- S. S. Ramalingam, Atlanta, USA
- H.-I. Schmolz, Halle, Germany
- I. Sekine, Chiba, Japan
- X. Paolotti, Paris, France
- P. Pfeiffer, Odense, Denmark
- S. V. Porceddu, Brisbane, Australia
- M. R. Posner, New York, USA
- S. Postel-Vinay, Villejuif, France
- A. Poyri, New Haven, Connecticut, USA
- D. Quinn, Los Angeles, California, USA
- S. Ramalingam, Atlanta, Georgia, USA
- M. Reck, Grosshansdorf, Germany
- B. Rini, Cleveland, Ohio, USA
- R. Rosell, Badalona, Spain
- A. D. Roth, Geneva, Switzerland
- R. Salazar, Barcelona, Spain
- M. Scartozi, Arconà, Italy
- N. Schmitz, Hamburg, Germany
- H.-I. Schmolz, Halle, Germany
- I. Sekine, Chiba, Japan
- Q. Shi, Rochester, Minnesota, USA
- A. F. Sobrero, Genoa, Italy
- G. Sonpavde, Birmingham, Alabama, USA
- S. Takahashi, Tokyo, Japan
- M. Toi, Kyoto, Japan
- E. Vilar, Houston, Texas, USA
- Y.-L. Wu, Guangzhou, China
- J. C.-H. Yang, Taipei, Taiwan
- S. Yano, Kanazawa, Japan

**Early drug development**

- J.-C. Soria, Villejuif, France

**Preclinical and experimental science**

- T. U. E. Helleday, Stockholm, Sweden

**Precision medicine**

- C. Swanton, London, UK

**Bioinformatics**

- M. Delorenzi, Lausanne, Switzerland

**BioTechnologies**

- E. Mardis, St. Louis, Missouri, USA

**Onco-Immunology**

- G. Coukos, Lausanne, Switzerland

**Statistics**

- M. Buyse, Brussels, Belgium

**Molecular and surgical pathology**

- I. Okamoto, Sapporo, Japan

**Onco-Immunology**

- J. B. Vermorken, Oxford, UK

**Cardiovascular and molecular pathology**

- F. Cavalli, Bellinzona, Switzerland

**Cardiovascular medicine**

- M. Reck, Munich, Germany

**Cancer control**

- B. Rini, Cleveland, Ohio, USA

**Cancer diagnostics**

- R. Rosell, Badalona, Spain

**Cancer prevention**

- A. D. Roth, Geneva, Switzerland

**Cancer therapy**

- R. Salazar, Barcelona, Spain

**Cancer therapy**

- M. Scartozi, Arconà, Italy

**Cancer therapy**

- N. Schmitz, Hamburg, Germany

**Cancer therapy**

- H.-I. Schmolz, Halle, Germany

**Cancer therapy**

- I. Sekine, Chiba, Japan

**Cancer therapy**

- X. Paolotti, Paris, France

**Cancer therapy**

- P. Pfeiffer, Odense, Denmark

**Cancer therapy**

- S. V. Porceddu, Brisbane, Australia

**Cancer therapy**

- M. R. Posner, New York, USA

**Cancer therapy**

- S. Postel-Vinay, Villejuif, France

**Cancer therapy**

- A. Poyri, New Haven, Connecticut, USA

**Cancer therapy**

- D. Quinn, Los Angeles, California, USA

**Cancer therapy**

- S. Ramalingam, Atlanta, Georgia, USA

**Cancer therapy**

- M. Reck, Grosshansdorf, Germany

**Cancer therapy**

- B. Rini, Cleveland, Ohio, USA

**Cancer therapy**

- R. Rosell, Badalona, Spain

**Cancer therapy**

- A. D. Roth, Geneva, Switzerland

**Cancer therapy**

- R. Salazar, Barcelona, Spain

**Cancer therapy**

- M. Scartozi, Arconà, Italy

**Cancer therapy**

- N. Schmitz, Hamburg, Germany

**Cancer therapy**

- H.-I. Schmolz, Halle, Germany

**Cancer therapy**

- I. Sekine, Chiba, Japan

**Cancer therapy**

- Q. Shi, Rochester, Minnesota, USA

**Cancer therapy**

- A. F. Sobrero, Genoa, Italy

**Cancer therapy**

- G. Sonpavde, Birmingham, Alabama, USA

**Cancer therapy**

- S. Takahashi, Tokyo, Japan

**Cancer therapy**

- M. Toi, Kyoto, Japan

**Cancer therapy**

- E. Vilar, Houston, Texas, USA

**Cancer therapy**

- Y.-L. Wu, Guangzhou, China

**Cancer therapy**

- J. C.-H. Yang, Taipei, Taiwan

**Cancer therapy**

- S. Yano, Kanazawa, Japan

**Executive Editor:** Lewis Rowett

**Editorial Office:** Paola Minotti Bernasconi, Giovannella Porcu, Annals of Oncology, Via Luigi Taddei 4, CH-6962 Viganello-Lugano, Switzerland
subscribers

A subscription to Annals of Oncology comprises 12 issues plus supplements in each volume. Prices include postage, and for subscribers outside the UK delivery is by Standard Air.

Annual Subscription Rate (Volume 26, 12 issues, 2015)

Institutional – Academic / Non profit only
Print and Online £1486.00/$2972.00/€2229.00
Online Only £1340.00/$2280.00/€1710.00
Print Only £1197.00/$2154.00/€1605.00

Institutional – Corporate
Print and Online £1657.00/$3174.00/€2576.00
Online Only £1425.00/$2580.00/€1937.00
Print Only £1279.00/$2318.00/€1763.00

Personal
Print and Online £1178.00/$2256.00/€1767.00
Please note: US$ rate applies to US & Canada, Euros applies to Europe, UK£ applies to UK and Rest of World.

There may be other subscription rates available, for a complete listing please visit www.annonc.oxfordjournals.org/subscriptions

Methods of payment.
(i) Cheque (payable to Oxford University Press, to
doi.org
DOI: 10.1093/annonc/mdu039
108-8386, Japan. Tel. +81 3 5444 5858. Fax. +81 3 3454 2929. E-mail: custserv.
Customer Service, Oxford University Press, 4-5-10-8F Shiba, Minato-ku, Tokyo
In Japan, please contact:
Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Email: jnls.cust.serv@oup.com. Tel (and answerphone outside normal
working hours): +81 3 5444 5858. Fax: +81 3 3454 2929. E-mail: custserv.
jp@oup.com
DOI: For information about DOIs and to resolve them, please visit http://www.
doi.org

Methods of payment. (i) Cheque (payable to Oxford University Press, to
Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford
OX2 6DP, UK) in GB£ Sterling (drawn on a UK bank), US$ Dollars (drawn on a
US bank), or EUR Euros (drawn on a US bank), or EUR Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford
Group Office, Oxford (bank sort code 20-65-18) (UK), overseas only Swift code
BARC GB 22 (GB£ Sterling to account no. 70299332, IBAN
GB89BARC20651870299332; US$ Dollars to account no. 66014600, IBAN
GB27BARC2065186014600; EUR Euros to account no. 78923655, IBAN
GB16BARC2065187923655). (iii) Credit card (Mastercard, Visa, Switch or
American Express).

Annals of Oncology (ISSN 0923-7534) is published monthly by Oxford University Press, Oxford, UK. The US annual print subscription or price is $2972.00. Airfreight and mailing in the USA by agent named Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11431.

Subscription records are maintained at Oxford University Press, Oxford, UK.

supplements, reprints and corporate sales
For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please email: special.
sales@oup.com, fax: +44 (0) 1865 353774 or visit www.oxfordjournals.org/sales.

permissions
For information on how to request permissions to reproduce articles/information from this journal, please visit www.oxfordjournals.org/permissions.

advertising
Advertising, inserts and artwork enquiries should be addressed to Advertising
and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon
Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax +44 (0)1865
353774; E-mail: jnlsadvertising@oup.com

environmental and ethical policies
Oxford Journals, a division of Oxford University Press, is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see http://www.oxfordjournals.org/ethicalpolicies.html for further information on environmental and ethical policies.

drug disclaimer
All reasonable precautions have been taken by the authors, editors and publisher to verify drug names and doses, the results of experimental work and the clinical findings published in this journal. The opinions expressed are those of the authors, and not necessarily those of the editors or publisher. The ultimate responsibility for the use and dosage of drugs mentioned in Annals of Oncology and in the interpretation of published material lies with the medical practitioner. The editors and publisher can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

© The European Society for Medical Oncology 2015

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

Typeset by Techset Composition India Private Limited, Chennai, India.
Printed by Bell and Bain Ltd., Glasgow, UK.
Annals of Oncology

Official Journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology

Volume 26, 2015 Supplement 2

13th International Congress on Targeted Anticancer Therapies (TAT 2015)

Paris, France, 2–4 March 2015

Guest Editors:
G. Giaccone, Washington, DC, USA
M.W. Lobbezoo, Harmelen, The Netherlands
J.-C. Soria, Villejuif, France

Funding: This publication is supported by an educational grant from Servier.